Please login to the form below

Not currently logged in
Email:
Password:

Valeant appoints company group chairman

Ari Kellen joins from McKinsey & Company

Fast-growing Canadian pharma company Valeant Pharmaceuticals has appointed Dr Ari Kellen as executive VP and company group chairman.

Dr Kellen joins from McKinsey & Company where he was a senior partner at the consultancy firm's mid-Atlantic office.

He spent 22 years at McKinsey leading a number of a studies for healthcare companies, including corporate strategies for boards and top management teams, business unit strategies for medical device, pharma and biotech, and health care services clients, and regional and country growth strategies.

J Michael Pearson, chairman and CEO of Valeant, said: "Ari's broad experience in developing comprehensive growth strategies for healthcare companies will be invaluable to us as we continue to expand our successful growth trends.

“After having worked with Ari for many years, I know that not only will he fit in well with the rest of the team, but he will be a strong advocate for the long-term shareholder focused culture at Valeant."

28th November 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

Research Partnership has joined Ashfield Advisory, the consulting division of healthcare marketing services company, Ashfield. As the market insights specialist...

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...